Aprea Therapeutics (APRE) Misses Q4 EPS by 49c

Aprea Therapeutics (NASDAQ: APRE) reported Q4 EPS of ($0.49). Revenue for the quarter came in at $210 thousand.

For earnings history and earnings-related data on Aprea Therapeutics (APRE) click here.

You May Also Be Interested In

• Citi cuts Lowe's price target to $260, keeps Buy rating
• John B. Sanfilippo & Son (JBSS) Misses Q4 EPS by 59c
• Antalpha Platform Holding Co. (ANTA) PT Lowered to $7.50 at B.Riley